These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 7438326)

  • 21. Modification of CCNU pharmacokinetics by misonidazole--a major mechanism of chemosensitization in mice.
    Lee FY; Workman P
    Br J Cancer; 1983 May; 47(5):659-69. PubMed ID: 6849803
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 5-Fluorouracil, 1,3-bis(2-chloroethyl)-1-nitrosourea, and 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea: effect on the human granulopoietic system.
    Lohrmann HP; Lepp KA; Schreml W
    J Natl Cancer Inst; 1982 Apr; 68(4):541-7. PubMed ID: 6951071
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chemosensitization of the nitrosoureas by 2-nitroimidazoles in the subcutaneous 9L tumor model: pharmacokinetic and structure-activity considerations.
    Wong KH; Wallen CA; Wheeler KT
    Int J Radiat Oncol Biol Phys; 1990 May; 18(5):1043-50. PubMed ID: 2140824
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vivo chemosensitization by misonidazole in sensitive and resistant tumor lines.
    Mulcahy RT; Siemann DW
    Cancer Res; 1983 Oct; 43(10):4709-13. PubMed ID: 6883329
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction of specific-locus and dominant lethal mutations in male mice by 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).
    Ehling UH; Adler ID; Favor J; Neuhäuser-Klaus A
    Mutat Res; 1997 Oct; 379(2):219-31. PubMed ID: 9357551
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emergence of nitrosourea resistant sublines of Lewis lung tumour following MeCCNU treatment in vivo.
    Stephens TC; Adams K; Peacock JH
    Br J Cancer; 1986 Feb; 53(2):237-45. PubMed ID: 3954945
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of Fluosol-DA/O2 on tumor-cell and bone-marrow cytotoxicity of nitrosoureas in mice bearing FSA-II fibrosarcoma.
    Teicher BA; Holden SA; Rose CM
    Int J Cancer; 1986 Aug; 38(2):285-8. PubMed ID: 3089945
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic profile of fotemustine in rat plasma by electrochemical detection.
    Bartosek I; Corada M; Dallarda S; Lucas C; Deloffre P; Guaitani A
    Xenobiotica; 1991 Feb; 21(2):235-42. PubMed ID: 2058178
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Measurement and characterization of the denitrosation of tauromustine and related nitrosoureas by glutathione transferases in liver cytosol from various species.
    Tuvesson H; Gunnarsson PO; Seidegård J
    Carcinogenesis; 1993 Jun; 14(6):1143-7. PubMed ID: 8508500
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mutagenicity of nitrosourea compounds for Salmonella typhimurium.
    Auletta AE; Martz AG; Parmar AS
    J Natl Cancer Inst; 1978 Jun; 60(6):1495-7. PubMed ID: 349171
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of nitrosoureas: levels of 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU) in organs of normal and Walker 256/B carcinoma bearing rats after i.v. bolus.
    Bartosek I; Russo RG; Cattaneo MT
    Tumori; 1984 Dec; 70(6):491-8. PubMed ID: 6531791
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanism of action of the nitrosoureas -- III. Reactions of bis-chloroethyl nitrosourea and bis-fluoroethyl nitrosourea with adenosine.
    Tong WP; Ludlum DB
    Biochem Pharmacol; 1979 Apr; 28(7):1175-9. PubMed ID: 444275
    [No Abstract]   [Full Text] [Related]  

  • 33. Nitrosoureas: a review of experimental antitumor activity.
    Schabel FM
    Cancer Treat Rep; 1976 Jun; 60(6):665-98. PubMed ID: 782694
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A method to determine the carbamoylating potential of 1-(2-chloroethyl)-1-nitrosoureas.
    Stahl W; Krauth-Siegel RL; Schirmer RH; Eisenbrand G
    IARC Sci Publ; 1987; (84):191-3. PubMed ID: 2960614
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sensitivity to 1,3-bis(2-chloroethyl)-1-nitrosourea and 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea of the EMT6 tumor in vivo as determined by both tumor volume response and in vitro plating assay.
    Twentyman PR
    Cancer Res; 1978 Aug; 38(8):2395-400. PubMed ID: 667838
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased mutagenicity of chloroethylnitrosoureas in the presence of a rat liver S9 microsome mixture.
    Suling WJ; Rice LS; Shannon WM
    J Natl Cancer Inst; 1983 Apr; 70(4):767-9. PubMed ID: 6220173
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cytochrome P-450-dependent formation of alkylating metabolites of the 2-chloroethylnitrosoureas MeCCNU and CCNU.
    Kramer RA
    Biochem Pharmacol; 1989 Oct; 38(19):3185-92. PubMed ID: 2818619
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Formulation and biological distribution of radiolabeled 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea in an animal tumor model.
    Castronovo FP; Potsaid MS; Kopiwoda S
    Cancer Res; 1980 Oct; 40(10):3473-4. PubMed ID: 7438035
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effects of BCNU (1,3-bis(2-chloroethyl)-1-nitrosourea) and CCNU (1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea) on glutathione reductase and other enzymes in mouse tissue.
    Maker HS; Weiss C; Brannan TS
    Res Commun Chem Pathol Pharmacol; 1983 Jun; 40(3):355-66. PubMed ID: 6622814
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.